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ABSTRACT
A DNA vaccine, SCIB1, incorporating two CD8 and two CD4 epitopes from TRP-2/gp100 was
evaluated in patients with metastatic melanoma. Each patient received SCIB1 via intramuscular
injection with electroporation. The trial was designed to ﬁnd the safest dose of SCIB1 which induced
immune/clinical responses in patients with or without tumour. Fifteen patients with tumor received
SCIB1 doses of 0.4-8 mg whilst 20 fully-resected patients received 2–8 mg doses. Twelve patients
elected to continue immunization every 3 months for up to 39 months. SCIB1 induced dose-
dependent T cell responses in 88% of patients with no serious adverse effects or dose limiting
toxicities. The intensity of the T cell responses was signiﬁcantly higher in patients receiving 4 mg
doses without tumor when compared to those with tumor (p < 0.01). In contrast, patients with
tumor showed a signiﬁcantly higher response to the 8 mg dose than the 4 mg dose (p < 0.03) but
there was no signiﬁcant difference in the patients without tumor. One of 15 patients with
measurable disease showed an objective tumor response and 7/15 showed stable disease. 5/20 fully-
resected patients have experienced disease recurrence but all remained alive at the cut-off date
with a median observation time of 37 months. A positive clinical outcome was associated with MHC-
I and MHC-II expression on tumors prior to therapy (p D 0.027).
We conclude that SCIB1 is well tolerated and stimulates potent T cell responses in melanoma patients. It
deserves further evaluation as a single agent adjuvant therapy or in combination with checkpoint
inhibitors in advanced disease.
KEYWORDS
Immunotherapy; vaccine;
melanoma; T-cell
Introduction
Checkpoint blockade has demonstrated anti-tumor responses
in approximately 10–55% of melanoma patients.1–4 However,
many patients do not respond5,6 and may beneﬁt from an effec-
tive vaccine that stimulates high avidity T cell responses either
as a single agent or in combination with checkpoint blockade.
TRP-2 and gp100 are both crucial to melanin production
and are therefore expressed by all pigment producing melano-
mas. Cloning of T cells from patients, showing spontaneous
rejection of their melanomas, identiﬁed their targets as TRP-
2180-188 and gp100174-190 and indicated that they were CD8
rejection epitopes.7,8 This demonstrated that, at least in these
patients, there was a T cell repertoire recognizing self-antigens
with sufﬁcient avidity to kill tumour cells. The question
remains as to whether an effective vaccine could stimulate these
T cells in a wider cohort of patients.
We have previously shown in preclinical models that a
DNA plasmid encoding T cell epitopes within the comple-
mentarity-determining regions of a human IgG1 antibody
(ImmunoBody)9 and injected with electroporation (EP)
stimulates high avidity T cell responses.10 T cell avidity is criti-
cally important in both viral infection and tumor models as
only high avidity T cells mediate viral clearance and tumor
eradication.11-16 EP increases DNA uptake over 1000-fold in
comparison to injection alone and has an adjuvant effect
resulting from local tissue damage and stimulation of pro-
inﬂammatory cytokines.17,18 ImmunoBody acts by direct
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uptake of the DNA into antigen presenting cells which is tran-
scribed, translated and processed, with epitopes being pre-
sented on the cell surface in combination with MHC.
ImmunoBody can also be taken up by both antigen present-
ing cells and non-antigen presenting cells and the transcribed
antibody protein secreted. The secreted antibody is internal-
ized via the high afﬁnity FcgR1 receptor (CD64) on antigen
presenting cells, and is then processed and epitopes cross pre-
sented on MHC-I. It is this combination of direct and cross
presentation that elicits T cells with sufﬁciently high avidity to
eradicate established tumors in preclinical models.9 Further-
more, the frequency and avidity of T cell responses induced
by ImmunoBody are superior to those induced by immuni-
zation with DNA encoding full-length antigen, using naked
peptides or peptides loaded onto dendritic cells.10,19-21
In this ﬁrst-in-human study, SCIB1 ImmunoBody, incor-
porating HLA-A0201 restricted epitopes from gp100 and
TRP-2 plus HLA-DR0401 and HLA-DR7/ DR53/DQ6
restricted epitopes from gp100 was assessed in HLA-A0201
melanoma patients with at least one of the relevant HLA class-
II types. The trial was designed to ﬁnd the optimal dose of
vaccine to induce immunological responses and to allow evalu-
ation of safety/tolerability and clinical responses.
Results
Patient treatment
The trial design is shown in Fig. 1 and patient demographics are
shown in Table 1. A total of 35 patients were recruited, all were
evaluated for toxicity and 33/35 for immunological responses.
Fifteen patients had tumor present at baseline and 20 patients
had fully-resected disease. The original premise for the study
was that patients without a high tumor load might respond bet-
ter to a cancer vaccine; however, ﬁrst-in-human clinical trials
are usually restricted to patients with advanced malignant dis-
ease. Although both patients with and without tumor present
could be recruited into the initial planned dose escalation phase,
most clinicians enrolled only patients with tumor (Part 1,
cohorts 1–3, doses 0.4-4 mg, Fig. 1, B). In the absence of any
obvious toxicity, the highest dose of SCIB1 (4 mg) was selected
to dose an expanded group of patients with no tumor present
(Part 2, cohort 1). During recruitment of this cohort advances in
the manufacturing methodology enabled us to generate plasmid
DNA at higher concentrations giving us the potential to admin-
ister a higher, 8 mg, dose. A further safety cohort of patients
receiving 8 mg was therefore added to the dose escalation phase
in patients with tumor (Part 1, cohort 4) and then an additional
cohort, again at 8 mg, was added to the expansion phase (Part 2,
cohort 2). Patients with or without tumor present were permit-
ted for this ﬁnal group as an objective tumor response had been
observed in a patient in the 8 mg safety cohort.
Dose escalation proceeded without dose limiting toxicity.
Twenty-ﬁve patients received ﬁve doses and completed the
study; 10 patients withdrew due to progressive disease, two
after one dose (non-evaluable for immune response), two after
three doses and six after four doses. In the 2 mg cohort all three
patients had their dose escalated to 4 mg after receiving at least
their ﬁrst three immunizations (Table 2). Twelve patients
received one or more doses of SCIB1 in the continuation phase
of treatment at approximately 3-monthly intervals, including
nine patients with resected disease. No patients received any
concurrent melanoma therapy. The data presented was col-
lected up to, and including, the point at which all patients had
completed dosing in the main part of the study. As the hypoth-
esis was that disease-free patients would elicit a stronger T cell
response than patients with tumor, the data was analysed
according to whether patients had tumor present or not at
study entry and then by dose level, rather than by dose alone.
Immune responses
Thirty-three patients were assessed for T cell responses by cul-
tured Elispot and/or proliferation assays (Tables 2, 3). The
gp100 HLA-A0201, CD8 epitope is nested within the HLA-
DR7/DR53/DQ6 epitope so use of the long peptide does not
discriminate between CD4 and CD8 responses The responses
to the short peptide are likely to be CD8 responses as small
Figure 1. Patient recruitment and analysis. (A) Participant ﬂowchart. Patients were initially recruited sequentially into Part 1, cohorts 1, 2 and 3. Resected patients were
then recruited into Part 2 cohort 1 at a dose of 4 mg. A further cohort of patients was recruited in parallel with Part 2 cohort 1 at a higher dose of 8 mg (Part 1 cohort 4)
and then Part 2 was expanded to dose patients at this 8 mg dose (Part 2 cohort 2). (B) Patient data was analysed based on whether tumor was present or not at screening
and then by dose level. One patient in each of Part 1 cohort 1 and cohort 3 only received a single injection and were replaced. Intra-patient dose escalation to 4 mg
permitted.
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hydrophobic peptides do not usually bind to HLA- DR7/DR53/
DQ6. This is consistent with the observation that six patients
responded only to the short CD8 peptide. We therefore counted
these responses separately. Conversely, responses observed with
the gp100 DR7/DR53/DQ6 long peptide could be against the
nested HLA-A2-restricted short peptide. Indeed, all patients
responding to the long peptide also react to the nested short pep-
tide. Twenty-six patients were evaluated by Elispot and the
results are summarized in Fig. 2. Six of eight tumor-bearing
patients and 17/19 tumor-free patients made a detectable Elispot
response. Two of the tumor-bearing patients received 4 mg
doses; one responded to three peptides (Fig. 2, A) whereas no
responses were seen in samples from the other patient (data not
shown). Six tumor-bearing patients received 8 mg doses and
strong Elispot responses were detected in ﬁve patients as exem-
pliﬁed by Fig. 2, B-D. Sixteen tumor-free patients received 4 mg
doses and 14 of them responded to at least one epitope with 10/
14 responding to all four epitopes (exempliﬁed by Fig. 2, E-H).
Four tumor-free patients received 8 mg doses and three of them
responded to at least two epitopes. The intensity of the responses
(maximal Elispot count) was signiﬁcantly higher in patients
without tumor in patients receiving 4 mg doses compared to
those with tumor receiving 4 mg (p < 0.01; Fig. 2, I). In contrast,
patients with tumor showed a signiﬁcantly higher response to
the 8 mg dose than the 4 mg dose (p < 0.03) whereas there was
no signiﬁcant difference between doses in the patients without
tumor (Fig. 2, I). This suggests that the lower dose of 4 mg was
sufﬁcient for the patients without tumor but a higher dose is
required to overcome the immunosuppression associated with
bulky tumors. None of the six fully-resected patients receiving
the 4 mg dose, who continued therapy and eventually received
at least 10 doses of SCIB1 responded to all four epitopes follow-
ing the initial ﬁve doses; however, all six responded to all four
epitopes following 10 SCIB1 administrations (Fig. 2, J). Overall,
of the 26 patients evaluated by Elispot, three patients did not
respond, three patients responded to one epitope, two patients
responded to two, two patients responded to three and 16
patients responded to all four epitopes.
Thirty-three patients were evaluated by proliferation and the
results are summarized in Fig. 3, Tables 2 and 3. Seven of 13
tumor-bearing patients and all 20 tumor-free patients made a
detectable proliferation response. A typical proliferation response
from a patient to all four epitopes is shown in Fig. 3, A-D. Only 1/3
tumor-bearing patients receiving 0.4 mg generated a proliferation
response, and that was only to a single peptide; 3/3 patients receiv-
ing 2 mg/4 mg doses, 12/17 patients receiving 4 mg doses and 6/10
patients receiving 8 mg doses responded to at least two peptides.
Proliferation responses to any peptide were observed after three or
more doses, but they continued to increase with continued admin-
istration of SCIB1. Two of the six fully-resected patients receiving
the 4 mg dose, who continued therapy and eventually received at
least 10 doses of SCIB1, responded with proliferative responses to
Table 1. Patient Demographics.
Tumor present at baseline Tumor not present at baseline Overall
Characteristic n % n % n %
Number 15 20 35
Age
Range 36–75 25–74 25–75
Median 64 60 60
Sex
Male 7 46.7 11 55.0 18 51.4
Female 8 53.3 9 45.0 17 48.6
Stage at study entry1
III 12 6.7 12 60.0 13 37.1
IV 14 93.3 8 40.0 22 62.8
M1a 2 14.3 5 62.5 7 31.8
M1b 6 42.9 2 25.0 8 36.4
M1c 6 42.9 1 12.5 7 31.8
Primary site
Head 3 20.0 23 9.5 5 14.3
Neck 1 6.7 1 4.8 2 5.7
Upper extremity 0 0 2 9.5 2 5.7
Lower extremity 3 20.0 7 33.3 10 28.6
Trunk 4 26.7 6 28.6 10 28.6
Mucosal 1 6.7 0 0 1 2.9
Other 3 20.0 2 9.5 5 14.3
Unknown 0 0 1 4.8 1 2.9
History
Superﬁcial spreading 6 40.0 11 52.4 17 48.6
Nodular 4 26.7 6 28.6 10 28.6
Lentigo maligna 2 13.3 0 0 2 5.7
Acral lentiginous 0 0 1 4.8 1 2.9
Other 3 30.0 2 9.5 5 14.3
Lactose dehydrogenase (LDH) at study
entry4
 450 IU/L 3 20.0 3 15.0 6 17.1
< 450 IU/L 12 80.0 17 85.0 29 82.9
1Tumor status prior to excision is shown for patients with resected disease at study entry.
2One patient had non-measurable lesions present and was stage III (M0).
3One patient had two primary sites recorded: head and other (right axillary fold).
4Values at week 0, apart from two patients where samples were not tested; screening values used.
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three epitopes following the initial ﬁve doses; however, ﬁve of six
had proliferation responses to three or more epitopes following 10
SCIB1 administrations (Fig. 3, E). Overall, six patients did not
respond, six patients responded to a single epitope, six patients
responded to two, ﬁve patients responded to three and 10 patients
responded to all four epitopes.
Patients showed similar responses in both assays used for
immune monitoring with 27/33 (82%) evaluable patients respond-
ing in the proliferation assay, 23/26 (89%) in the Elispot assay, 21/
26 (81%) in both assays and 29/33 (88%) in either assay. 67% (22/
33) of patients responded to all four epitopes, 85% to TRP2, 76% to
gp100A2, 76% to gp100DR4 and 67% to gp100DR7/DR53/DQ6
long peptide (shown in graphs as gp100DR7; Tables 2, 3). 100% of
patients without detectable tumor responded in either assay with
80% responding to all four epitopes. In contrast, only 69% of
patients with tumor present responded in either assay, with 46%
responding to all four epitopes.
Correlation of HLA phenotype and T cell responses are
shown in Table 3. Only one of the patients responding to the
gp100 long peptide did not express any of the HLA-DR7/DR53/
DQ6 alleles, but this could indicate a response to the nested
CD8 epitope. Ten of 25 patients responding to the gp100 HLA-
DR4 epitope did not express the HLA-DR4 allele suggesting that
this epitope has a more promiscuous binding and is not just
restricted to HLA-DR4. Indeed, the Immune Epitope Database
and Analysis Resource (IEDB) (http://tools.iedb.org/mhcii/) pre-
dicts that this epitope will bind better to HLA-DQ4 than HLA-
DR4 (supplementary Table 2).
Safety assessment
The vaccine was well tolerated (Table 4): 218 doses of SCIB1
were administered and there were no adverse events (AEs)
leading to discontinuation of study treatment. AEs were
Table 3. HLA Typing and Immune Responses.
Peptide response DR7/DR53/DQ6
Patient no. TRP-2 A2 gp100 A2 gp100 DR4 gp100 DR7 /DR53 /DQ6 DR7 DR53 DQ6
TUMOR PRESENT AT STUDY ENTRY
DOSE
DOSE D 0.4 mg
01-01 P
02-01
02-04
03-06 NE NE NE NE
DOSE D 2 mg/4 mg
01-16 P P P P
01-19 P P
DOSE D 4 mg
03-13 NE NE NE NE
04-16 P E P E P P E
05-05
DOSE D 8 mg
01-46 E E E E
01-49 E E E E
04-27 P E E E E
04-28 P E P E E Pc E
05-26 ND
05-27 P E P E
TUMOR NOT PRESENT AT STUDY ENTRY
DOSE
DOSE D 2 mg/4 mg
01-24 P P
DOSE D 4 mg
01-32 Ec E Pc E P E
01-34 P E P P P
01-37 P E P E E
02-21 P E E E E
02-33 P E
04-03 P
04-22 P P P E
05-08 P E P E E Pc E
05-09 P E E E E
05-11 Pc Ec Pc E P E P E
05-13 P P E P E P E
05-18 Ec P Ec P Ec P Ec
05-19 Pc Ec P Ec P E P Ec
05-21 P Ec Pc Ec Pc Ec Pc E
05-24 Pc Ec Pc E Pc E Pc E
DOSE D 8 mg
01-51 P E P E P E P E
01-54 E P E P E P E
04-43 P P P P
06-03 P E P E
Abbreviations: HLA, human leukocyte antigen; P, proliferation; E, Elispot; NE, non-evaluable; ND, not done; c, continued administration of SCIB1.
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reported as being related to either the study drug, SCIB1, or to
the study electroporation device/procedure. Overall, 28 patients
(80%) had AEs reported related to study drug; there was no
obvious difference in the rate of AEs in patients with escalating
doses or with tumor present at study entry and those with
resected disease. The most common of these study drug-related
events (>10%) were injection site hematoma (37%), injection
site pain (20%), fatigue (14%), blurred vision, headache, and
procedural pain (11%). In total, 32 patients (91%) experienced
AEs related to the electroporation device and procedure, most
commonly injection site hematoma (77%), injection site pain
(37%), procedural pain (17%), and fatigue (11%). Grade 3
AEs were infrequent and were considered related to SCIB1/EP
in only two patients (Grade 3 events of injection site
hematoma, injection site pain, and anxiety). The discomfort
associated with the EP device was generally described as tolera-
ble. There were no clinically signiﬁcant changes in laboratory
values during the study that were associated with SCIB1 admin-
istration (data not shown).
Clinical ﬁndings
The disease stage, time on study, SCIB1 dosing and disease pro-
gression for the 15 patients with tumor present at study entry
are shown in Fig. 4, A and in Table 2. Survival is shown in
Fig. 4, B and in Table 2. Pre- and post-study treatments are
shown in Fig. 4, A. Most patients had a number of prior lesions
that were treated with surgery or decarbazine. No patients
Figure 2. Generation of IFNg (A-H) in response to immunization with SCIB1. PBMC were isolated at the indicated study visits and cultured for 10 – 17 days at 37C with
HLA-A2-restricted TRP-2 peptide or with HLA-A2-restricted, HLA-DR4-restricted or HLA-DR7/DR53/DQ6-restricted gp100 peptides. IFNg was assayed on days 10 and 17 by
Elispot following a 24 hour re-stimulation with the appropriate peptide. Data is shown from one timepoint for each patient. Representative Elispot data is shown for
patient 04–16 (day 10), a patient with tumor present at screening and receiving 4 mg doses of SCIB1 (A); three patients with tumor present at screening and receiving
8 mg doses of SCIB1 (01-46 (day 10), 04–27 (day 17) and 04–28 (day 17) in panels B, C and D, respectively); and four fully-resected patients receiving 4 mg doses of SCIB1
(05-09 (day 10), 05–11 (day 10), 05–18 (day 17) and 05–21 (day 10) in panels E, F, G and H, respectively). The results shown are the mean number of IFNg producing cells
§ standard deviation (n D 4). Study visit days in the main study are denoted by the preﬁx “D” and in the continuation phase by “C” where Cx0y indicates x D weeks after
dosing and y D continuation dose number. (I) Maximum mean of four wells IFNg spot count for individual antigens determined for each responder. Non-parametric sta-
tistics (Mann Whitney test) were used for comparison of the results between cohorts. Antigen response deﬁnes the number of responses to any one epitope by any
patient against the number of potential responses for the number of patients tested. (J) Administration of >10 doses of SCIB1 conveys a broader range of epitope recog-
nition in fully-resected 4 mg patients compared to ﬁve administrations. The bar represents the median antigen recognition; the P value was calculated by the Mann Wit-
ney test. Individual colours represent individual patients i.e. 05–11 (black), 05–24 (red), 01–32 (blue), 05–19 (yellow), 05–21 (green) and 05–18 (purple).
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received checkpoint blockade prior to vaccination as these
treatments had not been approved at the time of the SCIB1
trial. Four patients received ipilimumab post-vaccination and
following disease progression. Three of these patients have died
and one is still alive. One patient with stage IV (M1b) disease
with lung metastases at study entry, treated at 8 mg, had a
RECIST partial response of 29 weeks duration as determined
during the main study period, per protocol (Fig. 4, C). After
completing the main study period, new subcutaneous lesions
identiﬁed progression of their disease prior to the patient’s ﬁrst
continuation visit. The patient subsequently received vemurafe-
nib and died 19 months after starting study participation. A
second patient with stage IV (M1b) disease with metastases in
the lung, lymph nodes, and subcutaneous space, treated at
4 mg, had a greater than 30% reduction in the size of their tar-
get lesions but progression of a non-target lesion (Fig. 4, D).
The patient had a single continuation dose of SCIB1 before a
new lesion was detected in the small bowel. Following further
tumor excision the patient was treated with vemurafenib and
died 31 months after starting the study. Both of these patients
had shown strong Elispot and/or proliferative responses to all
four SCIB1 epitopes. In addition to the patient with a partial
response, seven patients had a period of stable disease on the
study in excess of 16 weeks.
The disease stage, time on study and SCIB1 dosing for the 20
patients who were disease-free at study entry are shown in
Fig. 4, E and in Table 2. Disease recurrence is shown in Fig. 4, F
and in Table 2. Pre- and post-study treatments are shown in
Fig. 4, E. Most patients (17) had multiple lesions that were
treated with surgery prior to trial entry. No patients received
checkpoint blockade prior to vaccination as they had not been
approved at the time of the trial. One patient received ipilimu-
mab and one received nivolumab post-vaccination and both
are still alive. The longest follow up is available for the 16
Figure 3. T cell proliferation in response to immunization with SCIB1. PBMCs were isolated from patient 05–13 (tumor not present at screening; 4 mg dose) at the indi-
cated study visits (days) and cultured for up to 11 days at 37C following stimulation with (A) TRP-2 (HLA-A2-restricted) peptide; (B) gp100 (HLA-A2-restricted) peptide;
(C) gp100 (HLA-DR4-restricted) peptide; or (D) gp100 (HLA-DR7/DR53/DQ6-restricted) peptide. On days 7 and 11 cellular proliferation was assayed by the overnight incor-
poration of 3H-thymidine. The results shown are the mean of the calculated Proliferation Index (PI) § standard error of the mean (n D 3). (E) Administration of >10 doses
of SCIB1 conveys a broader range of epitope recognition in fully-resected 4 mg patients compared to ﬁve administrations. The bar represents the median antigen recogni-
tion; the P value was calculated by the Mann Witney test. Individual colours represent individual patients i.e. 05–11 (black), 05–24 (red), 01–32 (blue), 05–19 (yellow),
05–21 (green) and 05–18 (purple).
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patients treated with 2 mg and 4 mg of SCIB1; at the cut-off
date for reporting, all 16 patients were alive with a median
observation time of 39 months (range 33 to 52 months). At
2 years, 12 (75%) of these patients remained disease-free with-
out additional treatment beyond continued SCIB1. Disease-free
survival was largely independent of stage at screening with 7/9
(78%) of stage III patients and 5/7 (71%) of stage IV patients
alive and disease-free at 2 years. All patients with resected dis-
ease at study entry who received 8 mg doses of SCIB1 (who
were recruited later than the 4 mg cohort) remained alive and
disease-free at the data cut-off point.
Tumor analysis
Following an amendment to the original protocol, pre/post-
treatment tumors were obtained from 21/35 patients and
stained for expression of MHC-I/II, gp100/TRP-2 and PD-L1
plus inﬁltration of CD4, CD8 and Foxp3 positive cells (Table 5).
There was great variability in expression of these markers
between lesions from the same patient.
Initially the biopsies taken prior to vaccination were ana-
lysed to see if any of the markers could predict response to
SCIB1. Of interest was the ﬁnding that the pre-treatment
tumors of 13 patients showed strong MHC-II expression
(>15% of tumor cells expressing MHC-II) and this group of
patients with MHC-II positive tumors included seven patients
who remained alive and tumor-free post-resection and post-
SCIB1 treatment plus both of the patients with CT scan
ﬁndings of tumor regression. Of the eight patients whose pre-
treatment tumors did not express high levels of MHC-II, only
four were disease-free at the end of the main study period. Pre-
treatment tumor samples from eight patients showed a loss of
MHC-I (deﬁned as 80% of tumor cells showing MHC-I
expression in any pre-treatment biopsy sample). Five of these
Figure 4. Clinical ﬁndings and tumor regression in patients immunized with SCIB1. (A) Swimmer plot for patients with tumor present at study entry (n D 15). Information
about other treatments given post-SCIB1 was collected in follow-up; dates, duration and response data were not collected. (B) Kaplan-Meier analysis of the overall survival
of patients who had tumor at study entry and received at least three doses (2-8 mg) of SCIB1 (n D 10). (C) CT scans of lung lesions of patient 04–28 before and 6 months
after treatment with SCIB1. Lesion locations are indicated by arrows. (D) CT scans of lung lesions of patient 04–16 before and 9 months after treatment with SCIB1. (E)
Swimmer plot for patients with fully-resected tumor at study entry (n D 20). (F) Kaplan-Meier analysis of the recurrence-free survival of patients with fully-resected tumor
at study entry (n D 20).
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Table 5. Percentage Expression of Markers Present on Patient Tumor Biopsies.
Patient No. Pre/ Post MHC-I Tumor MHC-II Tumor gp100 TRP2 FoxP3 CD3 CD4 CD8 PD-L1 Tumor Tissue site
01-19 Pre 90 1 100 20 10 75 30 60 1 Skin
Pre 90 2 100 25 20 70 50 60 1 Skin
Pre 90 2 100 25 15 85 50 40 1 Neck node
Pre 90 3 100 10 10 90 50 30 3 Skin
Pre 95 1 100 10 7 80 60 55 1 Neck node
Pre 95 2 100 70 10 85 10 50 3 Parotid nodule
Pre 85 3 95 45 10 75 50 30 1 Skin
Pre 90 1 100 10 10 55 30 30 2 Skin with nodule
Pre 100 40 90 70 N/A N/A 0 N/A 2 Lymph node
Post 70 30 100 10 5 60 40 N/A 3 Lymph node
01-24 Pre 90 1 100 100 0 0 0 0 1 Skin
Pre 95 2 40 10 5 60 10 50 3 Lymph node
Pre 95 10 0 0 5 50 1 45 2 Lymph node
Pre 100 1 4 20 5 N/A 20 65 2 Skin
01-32 Pre 90 1 100 10 1 75 40 50 2 Skin
Pre 80 1 100 33 5 N/A 60 55 2 Skin
Pre 90 1 100 10 5 65 60 65 1 Skin
01-34 Pre 85 4 50 10 7 90 60 55 2 Skin
Pre 90 10 100 10 5 90 10 30 2 Lymph tissue
01-37 Pre N/A N/A N/A 70 N/A N/A N/A N/A 4 Lymph node
Pre 70 15 90 0 N/A 90 80 60 1 IIiac artery node
Pre 90 4 100 0 7 85 70 65 1 Skin
Pre 90 2 N/A N/A 0 N/A 0 N/A 1 Skin
Pre 80 3 100 0 10 75 45 60 2 Skin
Pre 90 5 100 0 10 85 50 70 2 Skin
Pre 85 1 100 0 15 70 30 55 2 Skin
Post 95 1 100 1 40 80 70 75 2 Skin
Post 95 3 100 0 15 90 50 65 N/A Skin
01-46 Pre 90 5 100 0 5 95 80 15 20 Lymph node
Pre 20 8 100 10 3 60 40 10 2 Left Lung
01-49 Pre 90 50 75 10 5 90 70 N/A 8 Right cheek
Pre 95 70 100 0 20 65 55 25 8 Lymph node
01-51 Pre 90 30 100 50 5 90 0 30 2 Skin right occiput
Pre 100 50 100 95 5 60 30 25 1 Skin right ear
Pre 90 80 50 0 2 50 0 50 2 Skin right ear
01-54 Pre 90 40 90 33 15 85 70 50 2 Skin
Pre 80 70 100 100 N/A N/A 50 N/A 1 Skin left ﬂank
Pre 80 60 33 20 5 90 70 30 2 Skin, left groin
02-21 Pre 90 1 80 15 10 70 30 40 1 Abdomen
Pre 90 10 100 0 7 75 30 85 1 Skin
Pre 90 90 100 15 5 90 50 45 2 Lymph node
02-33 Pre 80 10 0 0 10 N/A 50 N/A 1 Lymph node
04-03 Pre 50 1 90 5 10 80 40 65 2 Right neck
Post 95 50 95 10 5 80 40 35 2 Left breast
Post 80 10 70 20 7 60 50 70 2 Left chest
Post 90 30 70 30 10 75 50 90 2 Right breast
Post 90 10 50 10 2 90 0 20 1 Right upperarm
04-16 Pre 100 70 100 5 N/A 85 80 50 2 Lower back
Pre 100 80 95 5 5 0 60 50 2 Lower back
Pre 90 40 95 1 0 50 20 50 2 Lower back
Pre 90 80 67 75 5 85 50 N/A 4 Right ﬂank
Post 70 50 20 25 20 90 60 70 2 Left ﬂank
Post 90 60 10 10 1 75 30 50 2 Small bowel
04-27 Pre 85 70 50 5 20 85 80 50 2 Posteria right calf
Pre 90 10 100 5 20 90 80 50 1 Lateral right calf
Pre 100 1 100 90 20 90 30 15 1 Right leg
Pre 90 20 95 20 10 90 20 65 1 Right leg
Pre 95 10 90 20 10 95 90 40 2 Right ankle
Pre 100 1 100 5 5 75 0 25 1 Right shin
Pre 100 1 95 25 5 60 50 30 1 Right shin
Pre 100 20 95 30 20 60 90 35 1 Right shin
Pre 90 10 0 0 5 70 50 15 1 Right calf
Pre 95 2 100 20 15 60 70 10 1 Right ankle
Pre 80 5 100 5 25 70 80 80 1 Left arm
04-28 Pre 100 80 100 100 N/A N/A N/A N/A 2 Right upper back
Pre 100 80 100 100 N/A 50 50 50 2 Sentinel node local
Pre 100 40 100 100 N/A 100 50 N/A 1 Right posterior shoulder
Pre 50 40 100 60 N/A 100 10 80 8 Right scapula
Post 100 50 100 50 N/A 100 30 60 0 Left breast
Post 100 10 100 10 N/A 100 0 60 2 Right costal margin
Post 100 10 100 50 N/A 100 0 65 2 Right upper chest
Post 100 80 100 70 N/A N/A 0 N/A 0 Right shoulder
(Continued on next page)
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patients had disease recurrence and one had recurrence and
then died (patient 04–28). In contrast, of the 13 patients whose
tumors did not lose expression of MHC-I, only four were
not disease-free (including patient 04–16 who also had evi-
dence of tumor reduction). Fifteen patients expressed MHC-I
(>80% of tumor cells), MHC-II (>15% of tumor cells) or both
and only three of these patients had died/recurred or failed to
show a reduction in tumor burden in response to the vaccine.
Six patients had tumors that had lost expression of MHC-I
(80% of tumor cells) and had no elevated expression of
MHC-II (>15% of tumor cells). Only one of these patients
remains disease free. Clinical beneﬁt was superior in MHC-I/II
positive patients (Fishers exact test p D 0.027).
All pre-treatment tumors tested showed some loss of TRP-2
expression (between 10–100% of cells showing no expression)
and 14 showed some loss (10-100%) of gp100 expression.
Expression of PD-L1, inﬁltration of CD4, CD8 and Foxp3 posi-
tive cells or CD4:Foxp3 or CD8:Foxp3 ratios did not predict
disease recurrence or progression.
Tumors were obtained post-vaccination from six patients,
three who had tumor present and three who were fully-resected
at study entry. Tumors from one of the fully-resected patients
(05-09) failed to express either target prior to vaccination and
the patient did not beneﬁt from the vaccine as they experienced
tumor recurrence. One patient’s recurrent tumor (04-16) had a
reduction in expression of gp100 and TRP-2. One patient’s
post-vaccination tumor (01-19) showed a loss of MHC-I and
TRP-2. Two patients’ recurrent tumors excluded CD4T cells
(04-03 and 04–28) and one patient’s pre- and post-vaccination
tumors showed no obvious changes (01-37).
Discussion
We conducted a ﬁrst-in-human phase I/II trial to test the safety
and efﬁcacy of a gp100/TRP-2 antibody DNA vaccine, SCIB1,
in melanoma patients. SCIB1 was safe and well tolerated. Use
of the EP device to administer SCIB1 caused transient pain
and, on occasion, injection site hematoma but was successfully
given on 218 occasions, including administration to ﬁve
patients who have now each received 15–17 immunizations
over a period of up to 39 months. Discomfort from the EP pro-
cedure only limited treatment to three doses in a single patient.
The SCIB1 vaccine was developed to stimulate T cell
responses to both MHC-I and MHC-II restricted epitopes from
two different melanoma antigens. Eighty-eight percent of
patients responded to one or more epitopes and 67% of patients
responded to all four epitopes, with similar responses to both
antigens. There were signiﬁcantly stronger responses to the
8 mg dose than to the 2/4 mg doses in patients with tumor
present, indicating that the former is the most appropriate dose
for future studies in this population. The immune response rate
compares favourably with other vaccines targeting gp100 (80%
v 49%,22,23) but is a similar response rate to a DNA fusion vac-
cine targeting carcinoembryonic antigen (CEA,24), although
these comparisons are complicated by different assays being
used to quantify the immune response in each study.
Also in line with the CEA study, we show that both the T
cell Elispot responses were stronger in patients without tumor
present at screening than in patients with detectable tumor,
which suggests that tumor load may attenuate the response. It
also suggests that previous vaccine studies in patients with
tumor load may have underestimated the measurable effects
due to systemic or local immune suppression. SCIB1 mono-
therapy may therefore be particularly effective in early stage
patients with a low tumor burden. At present, interferon-a2a
and ipilimumab are licensed for the adjuvant treatment of
melanoma.25,26 Ipilimumab signiﬁcantly improved median
recurrence-free survival (RFS) from 17.1 to 26.1 months and
the 3-year RFS of resected high-risk stage III patients from 35%
to 47% when compared to placebo, but 52% of patients discon-
tinued treatment due to toxicity.25 Further follow-up has shown
that this improvement in RFS led to a signiﬁcant improvement
in overall survival.27 In the current study, all 20 of the fully-
resected patients were alive at data cut-off with a median obser-
vation time of 37 months (range 6 – 52 months) from study
entry; the median RFS has not been reached and there was min-
imal toxicity. The 2- and 3-year RFS for the stage III patients
was 67% and 56%, respectively, and was 71% at both 2 and
3 years for the stage IV patients.
To prevent recurrence of melanoma it would be ideal to
stimulate memory responses. In animal models, SCIB1 stimu-
lated memory T cell responses that continued to increase in
avidity as the T cells were selectively recruited into memory.19
Similarly, in this current study, patients have shown stronger
and broader responses following extended treatment with
SCIB1. All patients on continuation responded to all four epito-
pes after ﬁve continuation doses at 21 months or after 10
immunizations; this suggests that vaccination for the
Table 5. (Continued ).
Patient No. Pre/ Post MHC-I Tumor MHC-II Tumor gp100 TRP2 FoxP3 CD3 CD4 CD8 PD-L1 Tumor Tissue site
05-09 Pre 90 70 0 0 25 70 50 50 1 Left axillary node
Post 70 15 0 0 5 55 30 35 1 Left axillary node
Post 50 5 0 0 5 N/A N/A 20 1 Left axillary node
05-11 Pre 90 15 N/A N/A 10 N/A N/A N/A 2 Axilla lymph node
05-13 Pre 90 30 N/A N/A 5 N/A N/A N/A 2 Axilla lymph node
05-18 Pre 100 50 100 50 20 50 N/A 60 2 Left groin
05-19 Pre 90 50 45 0 15 60 50 30 4 Axilla lymph node
05-21 Pre 100 50 95 10 5 45 10 85 8 Pancreas
Patient numbers in black refer to patients who either remained recurrence-free or had evidence of tumor reduction post-SCIB1 treatment (patients 04–16 and 04–28).
Patient numbers in red refer to patients who had tumor recurrence/progression and/or died.
Post-tumor samples are shaded in blue.
Values in bold and blue refer to pre-treatment tumor samples that showed 80% MHC-I or >15% MHC-II expression.
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prevention of recurrence should continue for at least 2 years
post-surgery and that maintenance vaccination should be con-
sidered as it appears to improve the strength and breadth of the
T cell response to vaccine-encoded epitopes. The former maybe
related to memory but this is difﬁcult to assess as we did not
phenotype these responses. The latter may indicate de novo
stimulation of new populations of T cells.
Thirty-eight percent of the tumors biopsied had reduced
expression of MHC-I prior to vaccination, although none had
total loss. One of six patients’ tumors that were resected post-
vaccination showed MHC-I loss (80% of cells expressing
MHC-I) that was not apparent prior to treatment. Tumors
lacking MHC-I expression can resist T cell attack and become
the dominant cell type. Total loss of MHC-I is rare as it makes
cells susceptible to attack by natural killer (NK) cells, but when
it occurs it is usually due to loss or mutation of b2microglobu-
lin.28,29 Loss of the speciﬁc allele recognized by the T cells is
more frequent as this makes the tumor cells resistant to both T
cell and NK attack. Unfortunately, allele speciﬁc monoclonal
antibodies do not work in immunohistochemistry analyses on
parafﬁn embedded tissue and therefore allele loss could not be
assessed.
Most tumors do not express MHC-II; however, 62% of the
tumors in this study showed strong MHC-II expression prior
to vaccination. MHC-II expression on melanomas has previ-
ously been described as an indicator of poor prognosis.30-32
However, in this study 9/13 of the patients whose tumors
expressed MHC-II are either disease-free or their tumors
regressed after SCIB1 treatment. This suggests that MHC-II
expression could be a predictive biomarker of patients who are
likely to respond to immunization. A recent study has shown
that MHC-II positivity on tumors cells predicted response to
anti-PD-1/PD-L1 therapy.33 It also provides support for the
growing evidence that tumor-speciﬁc CD4T cells play a vital
role in anti-tumor immunity.34-37
Some of the cells within all of the patients’ pre-treatment
tumors showed a loss of TRP-2 (with 10–100% of cells showing
no expression) although, with the exception of one patient,
expression did not decrease further on post-treatment, recur-
rent tumors. This suggests that there is a either a pre-existing T
cell response to TRP-2 in patients which drives selection of
antigen loss variants or it is lost due to genetic mutation or epi-
genetic dysregulation. The loss of TRP-2 prior to vaccination
did not predict outcome; however, this could be explained by
the expression of gp100 which is also a target for the vaccine
and emphasizes the need for including more than one antigen
in the vaccine design. Targeting these two antigens may also
beneﬁt from combination with other drugs which alleviate
tumor immune suppression or epigenetic control. Indeed, pre-
clinical studies have shown that in combination with check-
point blockade, SCIB1 and SCIB2 (an ImmunoBody targeting
NY-ESO-1), induce increased inﬁltration and proliferation of T
cells that result in signiﬁcantly improved survival.21,39 In this
trial, no patients received checkpoint inhibitors prior to vacci-
nation but six patients (four with tumor and two with no tumor
at study entry) received ipilimumab or nivolumab post-vacci-
nation and three of these patients are still alive. Although these
patient numbers are low, this suggests that SCIB1 vaccination
may prime for responses to checkpoint inhibition.
In conclusion, SCIB1 is a novel class of anti-cancer immu-
notherapy that induces T cells which can cause tumor regres-
sion in patients with melanoma. The high frequency of
responses, their breadth and durability suggest SCIB1 is worthy
of further study in a larger cohort of patients. This is particu-
larly the case in the adjuvant setting, where all of the patients
responded immunologically and where absence of toxicity is
an important clinical consideration. Furthermore, the stimula-
tion of potent de novo immune responses by SCIB1 may pro-
vide an opportunity for synergistic combination therapy with
checkpoint inhibitors in late stage disease.
Materials and Methods
Study design and treatment plan
This study is an open label, phase I/II dose escalation study in
melanoma patients. The trial was designed to ﬁnd the optimal
dose of vaccine to induce immunological responses and to
allow evaluation of safety/tolerability and clinical responses.
Patients with stage III/IV melanoma (with or without tumor
present at study entry (Part1)) were accrued in sequential
cohorts to receive 0.4, 2 or 4 mg of SCIB1 via intramuscular
injection with EP. Patients with fully-resected stage III/IV dis-
ease (Part 2) were treated at the maximum tolerated dose
(MTD; or the highest dose administered in Part 1 if no MTD
was determined). SCIB1 was administered at two injection sites
every 3 weeks for three doses and then twice more at 12 and
24 weeks. Dose escalation was only permitted following a safety
evaluation by the Cohort Review Committee of a minimum of
three patients in each cohort followed up to the week 7 visit.
Dose-limiting toxicities (DLTs) were deﬁned as either Grade 3/
4 neutropenia with fever and/or infection or any non-hemato-
logical toxicity or autoimmunity/allergy equal to or greater
than Grade 3 (CTCAE, version 4.02). Patients receiving the
2 mg dose were permitted to escalate to the 4 mg dose in the
absence of DLTs after their ﬁrst three doses. Patients without
any intercurrent toxicity by week 28 were permitted to continue
treatment every 12–24 weeks for up to 5 years. All patients were
followed up for a minimum of 2 years after study end or until
death. The UK Gene Therapy Advisory Committee provided
ethical approval for the study, which was conducted in accor-
dance with the Declaration of Helsinki and with Good Clinical
Practice as deﬁned by the International Conference on Harmo-
nization. As no MTD had been reached at 4 mg in the initial
Part 1 dose escalation phase, a fourth cohort of ﬁve patients
with tumors present was recruited and dosed with 8 mg SCIB1
(Part 1, cohort 4) in parallel with the recruitment of resected
patients into the ﬁrst Part 2 cohort. This was possible due to
improvements in the manufacturing process for the DNA,
which enabled a higher concentration of plasmid DNA solution
to be prepared which, with the volume restrictions for intra-
muscular injection, enabled an 8 mg dose to be administered.
Once safety at this higher dose had been demonstrated, an
additional group of patients was then recruited into a second
Part 2 cohort to receive 8 mg doses (either with or without
tumor present at study entry).
Although, adjuvant interferon-a2a was a treatment option
for fully-resected patients, the physicians involved in this trial
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did not routinely use it as standard of care. Ipilimumab was not
licensed for adjuvant use when the patients were dosed. Ipili-
mumab and pembrolizumab became available for use as stan-
dard of care at a later date and, indeed, some of the patients
received these treatments if they had progressive disease or a
recurrence. The patients receiving SCIB1 therefore received no
concurrent therapy for their melanoma.
Eligibility criteria
Patients were eligible for enrolment if they had histologically
conﬁrmed stage III or IV melanoma. Part 1 comprised of
patients with either resected disease or patients with advanced
disease who had measurable disease evaluable by the Response
Evaluation Criteria in Solid Tumors (RECIST version 1.0). In
Part 2, recruitment was limited to patients with resected disease
(4 mg cohort) or patients with or without tumor present at
screening (8 mg cohort). In both parts, patients with fully
resected disease could not receive systemic therapy between
resection and study registration. All patients needed to be posi-
tive for HLA-A2 and at least one of HLA-DR4, HLA-DR7,
HLA-DR53 or HLA-DQ6. Other inclusion criteria included an
Eastern Cooperative Oncology Group performance status of
2 and adequate liver function and lymphocyte counts. Exclu-
sion criteria included the presence of brain metastases, a life-
expectancy of less than 3 months, any prior systemic anti-can-
cer treatment or immunosuppressive therapy within 4 weeks of
study entry, previous malignancy within 5 years of screening,
the presence of any electronic stimulation device, cardiac
abnormalities and women who were pregnant or lactating. All
patients provided written informed consent prior to enrolment.
Evaluations at baseline and during treatment
Screening procedures and assessments consisted of a complete
medical history, a full clinical examination, baseline electrocar-
diogram, ophthalmologic examination, assessment of vital
signs, HLA tissue typing, pregnancy test (if appropriate) and
standard biochemical, hematological and urine analysis. Tumor
status at screening was determined by a CT scan of the head,
thorax, pelvis and abdomen.
The safety and tolerability of SCIB1 and the EP device were
monitored throughout by clinical examination, assessment of
the injection site, evaluation of vital signs and laboratory param-
eters, recording of AEs and a patient tolerability questionnaire.
Patients with tumor at screening were further assessed at weeks
9, 18 and 28 along with a CT scan prior to any additional
SCIB1 dose given during continuation treatment. Patients were
followed up in clinic for a minimum of 2 years with CT scans
where appropriate for suspected disease progression.
Stimulation of na€ıve and memory immune responses and
the response to multiple injections were assessed by standard
proliferation and interferon-gamma (IFNg) Elispot assays at
baseline and before and after subsequent immunizations.
Detailed methodology for these assays (in compliance with
MIATA guidelines) and immunohistochemistry is reported in
supplementary data. For the proliferation assays, a patient was
designated as an immunological responder if on two or more
time points post-dosing the proliferation index (PI) was double
the pre-treatment PI; the PI was deﬁned as the mean peptide-
speciﬁc counts per minute (cpm) divided by the mean negative
control cpm at a given time point. For the Elispot assays, a
patient was designated as an immune responder if on two occa-
sions or more post-dosing the mean peptide-speciﬁc Elispot
response minus two Standard Deviations was greater than the
mean pre-treatment peptide-speciﬁc response plus one Stan-
dard Deviation (of this mean) and the peptide-speciﬁc Elispot
response was more than 50 spots per million peripheral blood
mononuclear cells (PBMCs).
Clinical study statistics
The primary endpoint for Part 1 of the study was the safety and
tolerability of SCIB1 administered by electroporation. No sam-
ple size was determined for this part as it was designed to seek
an MTD that could not be predicted in advance. The sample
size for Part 2 (4 mg dose) of the study was based on Fleming’s
single stage procedure.40,41 The highest immune response prob-
ability given the null hypothesis of no drug effect was set at 50%
and the lowest immune response probability of the alternative
hypothesis was set at 75%. This requires the study of at least 13
patients for a two-sided signiﬁcance of 0.05 and 80% power.
The sample size for the expansion of Part 2 (8 mg dose) was
also based on Fleming’s single stage procedure. As three
patients (up to six) were to be enrolled in the Part 1 4 mg
cohort, an additional 10 patients were planned to provide a
total of 13 patients receiving the same dose.
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